

# Andrew M Tershakovec

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1982898/publications.pdf>

Version: 2024-02-01

10  
papers

679  
citations

933447

10  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. <i>Atherosclerosis</i> , 2012, 223, 251-261.	0.8	203
2	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	2.7	93
3	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2008, 102, 1495-1501.	1.6	80
4	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease—Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illin. <i>American Journal of Cardiology</i> , 2008, 102, 1489-1494.	1.6	75
5	Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study). <i>American Journal of Cardiology</i> , 2011, 108, 523-530.	1.6	59
6	Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study). <i>American Journal of Cardiology</i> , 2010, 105, 656-663.	1.6	45
7	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
8	Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. <i>Atherosclerosis</i> , 2014, 237, 829-837.	0.8	32
9	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	1.5	31
10	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	2.3	28